icon-folder.gif   Conference Reports for NATAP  
 
  65th Annual Meeting of the
American Association for the
Study of Liver Diseases
Boston, MA Nov 7-11 2014
Back grey_arrow_rt.gif
 
 
 
SVR12 Rate of 96.2% in 209 HCV Genotype 1-infected Null Responders Treated With ABT-450/r/Ombitasvir and Dasabuvir With or Without Ribavirin
 
 
  Reported by Jules Levin
AASLD 2014 Nov 7-11 Boston
 
Ira M Jacobson1, Jean-Francois DuFour2, Jeff rey Enejosa3, Robert J de Knegt4, Peter Ferenci5, Hendrik Reynaert6, Adrian M Di Bisceglie7, Lois Larsen3, Lino Rodrigues, Jr3, Thomas Podsadecki3, Donald Jensen8, Fred Poordad9 1Weill Cornell Medical College, New York, New York, United States; 2University Clinic for Visceral Surgery and Medicine, Bern, Switzerland; 3AbbVie Inc., North Chicago, Illinois, United States; 4Erasmus MC, Rott erdam, The Netherlands; 5Universitaetsklinik fuer Innere Medizin III, Vienna, Austria;
6Universitair Ziekenhuis Brussels, Brussels, Belgium; 7Saint Louis University Liver Center, Saint Louis University, St. Louis, Missouri, United States; 8Center for Liver Diseases, University of Chicago Medical Center Chicago, Chicago, Illinois, United States; 9The Texas Liver Insti tute/University of Texas
Health Science Center, San Antonio, Texas, United States

AASLD1.gif

AASLD2.gif

AASLD3.gif

AASLD4.gif

AASLD5.gif

AASLD6.gif

AASLD7.gif

AASLD8.gif

AASLD9.gif

AASLD10.gif

AASLD11.gif